The AT(N) classification paradigm for defining Alzheimer’s disease (AD) is based on biomarkers of β-amyloid deposition (A), pathologic tau (T), and neurodegeneration (N) [1]. The gene discussed is MAPT; the disease is Alzheimer disease.